NCT04576000 (PROPHETIC) is a clinical trial of Janus Kinase Inhibitor in Ulcerative Colitis, sponsored by Alimentiv Inc..

Who is sponsoring NCT04576000?

NCT04576000 is sponsored by Alimentiv Inc..

What drugs are being tested in NCT04576000?

Interventions in NCT04576000: Janus Kinase Inhibitor.

What condition does NCT04576000 study?

NCT04576000 studies Ulcerative Colitis.

Is NCT04576000 still recruiting?

NCT04576000 is currently terminated. Last updated 4 January 2022.

Last reviewed 2022-01-04 · How we verify

NCT04576000: PROPHETIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Terminated Last updated 4 January 2022

What this trial tests

trial testing Janus Kinase Inhibitor in Ulcerative Colitis in 3 participants. Terminated before completion.

Timeline

25 August 2020

Primary endpoint
15 December 2020

2 December 2021

Quick facts

Lead sponsor	Alimentiv Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	3
Start date	25 August 2020
Primary completion	15 December 2020
Estimated completion	2 December 2021
Sites	1 location across Netherlands

Drugs / interventions tested

Janus Kinase Inhibitor — full drug profile →

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

Alimentiv Inc. — full company profile →

Who can join

18 and older, any sex, with Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to provide new mechanistic insights into the molecular determinants of response or nonresponse to Janus Kinase inhibitor therapy and the biological heterogeneity that exists in Ulcerative Colitis. This study will include patients who are initiating Janus Kinase inhibitor therapy according to standard of care. This study consists of: * Part 1: 8 or 10 week induction therapy followed by an 8-week maintenance therapy * Part 2: Patients who continue Janus Kinas inhibitor therapy after part 1 will be followed further for a total of 2 years, or until discontinuation of Janus Kinase inhibitor therapy (whichever is first)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Liu E, Aslam N, Nigam G, Limdi JK. · · 2022 · cited 32× · PMID 35462642 · DOI 10.7573/dic.2021-11-4

Verify or expand the search:

Other trials of Janus Kinase Inhibitor

Trials testing the same drug.

NCT06660329 — Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome · Phase 4 · enrolling by invitation
NCT05451615 — Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis · Phase 3 · unknown
NCT06561256 — JAK Inhibitors' Efficacy in Bullous Pemphigoid · completed

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Alimentiv Inc. trials

Trials by the same sponsor.

NCT06997965 — Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD · Phase 4 · not yet recruiting
NCT06257706 — VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease · Phase 4 · recruiting
NCT06670638 — Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Pe · recruiting
NCT05252273 — Assessment of Patients With Acute Pouchitis Treated With Antibiotics · suspended
NCT04259138 — Determination of the Optimal Treatment Target in Ulcerative Colitis · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04576000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alimentiv Inc.
Last refreshed: 4 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04576000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing